Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.78 | 6.97 | — | — | — | — | 14.90 | — | — | — | — | — | — | — | — | — | — | — | — | 1.23 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.03 | 1.47 | 17.18 | 6.14 | 4.19 | 4.95 | 1.03 | 4.63 | 5.51 | 6.64 | 15.42 | 8.89 | 6.25 | 10.89 | 10.73 | 7.83 | 10.78 | 8.15 | 16.04 | 0.90 | 14.52 |
| — | -70.3% | +1563.4% | +32.5% | -23.8% | -25.5% | -93.3% | -47.9% | -12.0% | -39.0% | +43.7% | +13.5% | -42.0% | +33.6% | -33.1% | +766.3% | -25.8% | -56.5% | -15.1% | -95.4% | +436.9% | |
| P/B Ratio | 3.35 | 8.85 | 20.84 | 7.25 | 3.09 | 1.98 | 1.34 | 1.51 | 1.77 | 1.70 | 2.47 | 2.53 | 1.99 | 2.14 | 1.77 | 1.90 | 2.03 | 1.69 | 2.07 | 1.89 | 3.87 |
| — | +347.4% | +1453.8% | +379.0% | +74.7% | +16.4% | -45.6% | -40.2% | -11.3% | -20.7% | +39.6% | +33.2% | -1.7% | +27.0% | -14.5% | +0.9% | -47.7% | -48.1% | -19.7% | -58.0% | +50.5% | |
| P/FCF | — | — | — | — | — | — | 2.82 | — | — | — | — | — | — | — | — | — | — | — | — | 1.16 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -92.8% | — | |
| EV / EBITDA | — | 5.05 | — | — | — | — | 4.94 | — | — | — | — | — | — | — | — | — | — | — | — | 0.94 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 5.47 | — | — | — | — | 5.42 | — | — | — | — | — | — | — | — | — | — | — | — | 0.94 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.1% | 99.0% | -73.2% | 80.5% | -107.9% | 57.3% | 96.1% | 70.2% | 48.8% | 34.4% | 45.8% | 29.9% | 57.2% | 52.6% | 78.5% | 59.2% | 50.6% | 60.3% | 29.3% | 94.2% | 54.2% |
| — | +72.7% | -176.2% | +14.6% | -321.1% | +66.8% | +109.8% | +134.9% | -14.6% | -34.6% | -41.6% | -49.5% | +12.9% | -12.9% | +168.3% | -37.1% | -6.6% | +8.8% | -60.6% | +80.6% | -34.3% | |
| Operating Margin | -94.6% | 27.1% | -1304.0% | -190.0% | -176.3% | -296.3% | 13.6% | -242.1% | -256.6% | -251.3% | -395.4% | -287.7% | -224.7% | -366.0% | -345.7% | -184.3% | -268.0% | -191.5% | -321.9% | 78.7% | -186.4% |
| — | +109.1% | -9671.0% | +21.5% | +31.3% | -17.9% | +103.4% | +15.8% | -14.2% | +31.3% | -14.4% | -56.1% | +16.2% | -91.1% | -7.4% | -334.3% | -43.8% | +19.2% | -38.0% | +131.4% | -1421.3% | |
| Net Margin | -113.8% | 21.0% | -1408.6% | -221.3% | -208.3% | -331.8% | 6.8% | -241.3% | -246.3% | -237.7% | -405.4% | -283.1% | -214.0% | -360.7% | -348.4% | -191.2% | -284.7% | -208.8% | -345.3% | 73.8% | -189.8% |
| — | +106.3% | -20711.8% | +8.3% | +15.4% | -39.6% | +101.7% | +14.8% | -15.1% | +34.1% | -16.4% | -48.1% | +24.8% | -72.7% | -0.9% | -359.3% | -50.0% | +20.2% | -30.1% | +134.2% | -2235.5% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -107.0% | 48.9% | -145.5% | -50.8% | -33.0% | -29.1% | 2.3% | -18.2% | -18.3% | -14.3% | -18.0% | -18.6% | -16.1% | -16.5% | -13.6% | -11.1% | -12.6% | -10.3% | -10.6% | 48.0% | -12.1% |
| — | +268.4% | -6482.9% | -178.6% | -80.0% | -102.6% | +112.6% | +2.1% | -14.0% | +13.3% | -32.7% | -67.9% | -27.3% | -60.2% | -28.8% | -123.1% | -4.8% | +4.9% | +1.9% | +511.6% | -658.0% | |
| ROA | -42.2% | 6.2% | -22.7% | -13.7% | -11.2% | -13.2% | 1.3% | -10.4% | -11.0% | -8.8% | -10.5% | -10.4% | -9.4% | -10.1% | -8.4% | -7.0% | -8.2% | -6.9% | -7.2% | 30.7% | -7.1% |
| — | +147.1% | -1882.0% | -32.1% | -2.3% | -49.5% | +112.1% | +0.2% | -16.5% | +12.3% | -24.8% | -49.2% | -14.4% | -46.2% | -17.6% | -122.7% | -15.1% | -2.6% | -13.6% | +515.0% | -502.2% | |
| ROIC | -39.4% | 24.2% | -30.8% | -12.4% | -13.5% | -21.8% | 3.6% | -12.6% | -12.0% | -9.4% | -11.4% | -12.5% | -11.7% | -12.0% | -9.9% | -8.3% | -9.4% | -7.9% | -9.8% | 57.1% | -13.2% |
| — | +211.2% | -960.9% | +1.7% | -12.8% | -132.6% | +131.5% | -0.6% | -1.9% | +21.7% | -14.9% | -51.0% | -24.7% | -50.8% | -0.7% | -114.5% | +28.5% | +31.8% | +32.7% | +451.4% | -539.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.54 | 0.96 | 3.37 | 2.54 | 1.66 | 0.36 | 0.29 | 0.32 | 0.28 | 0.46 | 0.44 | 0.29 | 0.25 | 0.23 | 0.20 | 0.18 | 0.16 | 0.14 | 0.13 | 0.11 | 0.18 |
| — | +164.2% | +1057.6% | +702.7% | +495.5% | -20.2% | -33.3% | +10.3% | +11.7% | +102.0% | +117.7% | +56.0% | +59.5% | +60.8% | +57.7% | +61.9% | -15.2% | -15.3% | -8.3% | -41.0% | +25.8% | |
| Debt / EBITDA | — | 2.09 | — | — | — | — | 4.97 | — | — | — | — | — | — | — | — | — | — | — | — | 0.27 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.38 | 2.86 | 2.62 | 2.38 | 2.66 | 3.13 | 2.93 | 2.69 | 3.05 | 3.53 | 3.59 | 2.57 | 2.87 | 3.21 | 3.46 | 3.19 | 3.53 | 4.06 | 3.73 | 3.98 | 3.84 |
| — | -8.6% | -10.6% | -11.6% | -12.6% | -11.4% | -18.2% | +4.8% | +6.2% | +9.8% | +3.6% | -19.4% | -18.7% | -20.9% | -7.0% | -19.8% | -8.0% | -15.0% | -37.3% | -39.0% | -36.8% | |
| Quick Ratio | 2.38 | 2.86 | 2.62 | 2.38 | 2.66 | 3.13 | 2.93 | 2.69 | 3.05 | 3.53 | 3.59 | 2.57 | 2.87 | 3.21 | 3.46 | 3.19 | 3.53 | 4.06 | 3.73 | 3.83 | 3.84 |
| — | -8.6% | -10.6% | -11.6% | -12.6% | -11.4% | -18.2% | +4.8% | +6.2% | +9.8% | +3.6% | -19.4% | -18.7% | -20.9% | -7.0% | -16.8% | -8.0% | -15.0% | -37.3% | -40.0% | -36.8% | |
| Interest Coverage | -3.31 | 3.91 | -9.34 | -4.47 | -3.70 | -5.45 | 1.71 | -4.44 | -71.68 | -117.02 | -31.10 | -45.25 | -37.10 | -63.34 | -23.20 | -12.92 | -11.68 | -8.94 | -11.52 | 48.30 | -7.71 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RGNX stock.
REGENXBIO Inc.'s current P/E is -1.8x. The average P/E over the last 1 quarters is 7.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
REGENXBIO Inc.'s current operating margin is -94.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking REGENXBIO Inc.'s business trajectory between earnings reports.